Comparative Pharmacology
Head-to-head clinical analysis: NORETHIN 1 35E 28 versus NYLIA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHIN 1 35E 28 versus NYLIA 1 35.
NORETHIN 1/35E-28 vs NYLIA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive. Ethinyl estradiol suppresses FSH and LH, preventing ovulation. Norethindrone alters cervical mucus and endometrial lining, inhibiting sperm penetration and implantation.
Combination oral contraceptive consisting of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial lining.
One tablet orally once daily for 28 days (21 active tablets containing norethindrone 1 mg and ethinyl estradiol 35 mcg, followed by 7 inert tablets).
One tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no medication. Continuous sequential regimen.
None Documented
None Documented
Norethindrone: terminal elimination half-life approximately 8-11 hours. Ethinyl estradiol: terminal elimination half-life approximately 10-20 hours (mean ~13 hours). Clinical context: Steady-state achieved within 5 days; once-daily dosing maintains therapeutic levels.
Norethindrone: 5-14 hours (mean ~8 hours); Ethinyl estradiol: 7-36 hours (mean ~14 hours). Clinically, steady-state is achieved within 5-7 days.
Norethindrone is excreted primarily in urine as glucuronide and sulfate conjugates, with about 50-60% excreted renally; approximately 20-30% is excreted in feces via biliary elimination. Ethinyl estradiol is excreted in urine (40-60%) and feces (20-40%) after enterohepatic recirculation.
Renal: 40-60% (as metabolites, mainly ethinyl estradiol glucuronide and sulfate conjugates and norethindrone metabolites). Biliary/fecal: 30-50% (as conjugates and metabolites).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive